{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:49:34Z","timestamp":1778262574539,"version":"3.51.4"},"reference-count":27,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Netherlands Scientific Organization","award":["KJPB12.028"],"award-info":[{"award-number":["KJPB12.028"]}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["17OKG04"],"award-info":[{"award-number":["17OKG04"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,8,26]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have shown that the effect on achieving (clinical) remission, frequency and severity of relapses is equivalent for both therapies, but there is accumulating data that the long-term safety profile of RTX might outperform CYC. Combination of RTX with low-dose CYC (LD-CYC) has been investigated in only a few uncontrolled cohort studies, in which clinical remission and a favourable immunological state with low relapse rates was quickly achieved. In this randomised controlled trial, we aim to investigate whether the combination treatment (RTX+LD\u2009CYC) is superior in comparison to standard care with RTX only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is an open-label, multicentre, 1:1 randomised, prospective study for patients with AAV with generalised disease, defined as involvement of major organs, that is, kidneys, lungs, heart and nervous system. In total, 100 patients will be randomised 1:1 to receive either remission induction therapy with standard of care (RTX) or combination treatment (RTX+LD\u2009CYC) in addition to steroids and both arms are followed by maintenance with RTX retreatments (tailored to B-cell and ANCA status). Our primary outcome is the number of retreatments needed to maintain clinical remission over 2\u2009years. Secondary outcomes are relevant clinical endpoints, safety, quality of life and immunological responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has received approval of the Medical Ethics Committee of the Leiden University Medical Center (P18.216, NL67515.058.18, date: 7 March 2019). The results of this trial (positive and negative) will be submitted for publication in relevant peer-reviewed publications and the key findings presented at national and international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03942887\">NCT03942887<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061339","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:05:41Z","timestamp":1663769141000},"page":"e061339","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03942887","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-8138","authenticated-orcid":false,"given":"Ebru","family":"Dirikgil","sequence":"first","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-7566","authenticated-orcid":false,"given":"Jolijn R","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura S van","family":"Dam","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obbo W","family":"Bredewold","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argho","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline T","family":"Jonker","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"},{"name":"Department of Nephrology, Alrijne Hospital, Leiderdorp, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius","family":"Soonawala","sequence":"additional","affiliation":[{"name":"Department of Nephrology, HagaZiekenhuis, Den Haag, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde H F","family":"Remmelts","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Meander Medical Centre, Amersfoort, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastiaan","family":"van Dam","sequence":"additional","affiliation":[{"name":"Noordwest Ziekenhuisgroep, Alkmaar, Noord-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem Jan","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"},{"name":"Department of Internal Medicine, St. Antoniusziekenhuis, Nieuwegein, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Rotmans","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ton","family":"Rabelink","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Y K Onno","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"2025121605414684000_12.9.e061339.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket445"},{"key":"2025121605414684000_12.9.e061339.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"2025121605414684000_12.9.e061339.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"2025121605414684000_12.9.e061339.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277"},{"key":"2025121605414684000_12.9.e061339.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.103"},{"key":"2025121605414684000_12.9.e061339.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"2025121605414684000_12.9.e061339.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"2025121605414684000_12.9.e061339.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206404"},{"key":"2025121605414684000_12.9.e061339.9","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ekir.2021.08.002","article-title":"Clinical practice audit on the management of antineutrophil cytoplasmic antibody-associated vasculitis in the Netherlands","volume":"6","author":"Dirikgil","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025121605414684000_12.9.e061339.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1944"},{"key":"2025121605414684000_12.9.e061339.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209925"},{"key":"2025121605414684000_12.9.e061339.12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025121605414684000_12.9.e061339.13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025121605414684000_12.9.e061339.14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025121605414684000_12.9.e061339.15","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology"},{"key":"2025121605414684000_12.9.e061339.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"2025121605414684000_12.9.e061339.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.34583"},{"key":"2025121605414684000_12.9.e061339.18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025121605414684000_12.9.e061339.19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025121605414684000_12.9.e061339.20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013111233"},{"key":"2025121605414684000_12.9.e061339.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231"},{"key":"2025121605414684000_12.9.e061339.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212768"},{"key":"2025121605414684000_12.9.e061339.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212878"},{"key":"2025121605414684000_12.9.e061339.24","doi-asserted-by":"crossref","unstructured":"Smith RJD , Merkel P . A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease [abstract], 2019. Available: https:\/\/acrabstracts.org\/abstract\/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease\/","DOI":"10.1093\/ndt\/gfaa146.LB004"},{"key":"2025121605414684000_12.9.e061339.25","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.20"},{"key":"2025121605414684000_12.9.e061339.26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"2025121605414684000_12.9.e061339.27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:41:54Z","timestamp":1765892514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,21]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2022-061339"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061339","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}